Vaginal Dryness, Bladder Urgency, and Mental Health: The Psychological Burden of GSM Nobody Talks About
Genitourinary syndrome of menopause affects 40 to 54% of postmenopausal women, does not resolve without treatment, and carries a psychological burden on body image, sexual intimacy, daily freedom, and self-concept that almost no one is discussing. That silence is part of what makes it worse.
By Dr. Julie Rashkis, Psy.D. | Licensed Psychologist | Menopause Society Certified Practitioner | therapyformidlife.com
'I don't go anywhere without mapping the bathrooms first. I know where every restroom is in every building I regularly visit. I've started declining invitations because I can't predict when I'll need one, and I can't always get there in time. I haven't told my doctor because I don't know how to say it. It feels like something I should be managing on my own. It feels like my body has humiliated me.'
This is genitourinary syndrome of menopause and this is what it does to a woman's life when it goes untreated. GSM is the umbrella term for a cluster of physical changes driven by estrogen loss in postmenopause, affecting the vagina, vulva, urethra, and bladder. It encompasses vaginal dryness, burning, irritation, and painful intercourse; urinary urgency, frequency, leaking, and recurrent urinary tract infections. It is chronic, progressive, and unlike the hot flashes of perimenopause it does not resolve on its own. Without treatment, it typically worsens over time.
This article addresses something that almost no psychologist-authored content currently addresses: the psychological burden of GSM. Not the physical symptoms themselves, which are well-described in medical literature, but what they do to a woman's experience of her body, her sexual relationship, her sense of freedom and control, and her willingness to seek help. The shame, the avoidance, the way GSM quietly reorganizes a woman's life around managing and concealing what her body is doing this is mental health territory, and it belongs in a psychological conversation.
What GSM Actually Is — and Why It Matters Psychologically
Genitourinary syndrome of menopause was named in 2014 by a consensus of the North American Menopause Society (now The Menopause Society) and the International Society for the Study of Women's Sexual Health, replacing the older terms vulvovaginal atrophy and atrophic vaginitis terms that were both clinically inadequate and, for many women, deeply aversive. The new terminology acknowledges what the older terms missed: that this is a syndrome affecting not only vaginal tissue but the entire urogenital system, with symptoms that fall into three distinct clusters.
Symptom cluster: Genital symptoms
What it includes: Vaginal dryness, burning, itching, irritation, soreness, abnormal discharge
Prevalence in postmenopausal women: Vaginal dryness: 27-55%. Most commonly reported symptom in postmenopausal women
Symptom cluster: Sexual symptoms
What it includes: Lack of lubrication, pain or discomfort with intercourse (dyspareunia), reduced arousal, difficulty with orgasm, postcoital bleeding
Prevalence in postmenopausal women: Dyspareunia: 12-45%. Female sexual dysfunction affecting 68-86.5% of menopausal women overall
Symptom cluster: Urinary symptoms
What it includes: Urgency, increased frequency, urinary leaking/incontinence, painful urination (dysuria), nocturia, recurrent urinary tract infections
Prevalence in postmenopausal women: Urinary urgency and frequency: 57.7% in qualitative studies. Urinary symptoms have greater impact on quality of life than genital symptoms alone
Between 40 and 54% of postmenopausal women are affected by GSM. Around 60% of those affected have never received a diagnosis. Only a fraction seek consultation and the research is clear on why: embarrassment, shame, and the normalized belief that these symptoms are an unavoidable and unaddressable feature of aging. GSM is chronically underdiagnosed not because it is rare or difficult to identify, but because the silence around it in clinical settings, in social conversation, and in women's own internal experience prevents the conversation that would lead to treatment.
The clinically critical distinction between GSM and most other menopausal symptoms: it does not improve without treatment. Vasomotor symptoms, including hot flashes and night sweats, tend to diminish over the postmenopausal years for most women. GSM does the opposite. Without intervention, the estrogen-depleted urogenital tissues become progressively more atrophic, more vulnerable, and more symptomatic. A woman who is managing mild vaginal dryness at 52 without treatment is, on average, experiencing more significant symptoms at 57 and 62. The window for relatively straightforward intervention narrows the longer treatment is deferred.
"Unlike vasomotor symptoms, which tend to diminish over time, GSM symptoms rarely resolve spontaneously and in most cases deteriorate if left untreated, negatively affecting patients' confidence and intimacy with their partners. Around 60% of affected women have never received a diagnosis not because GSM is rare, but because the silence around it prevents the conversation that would lead to treatment." — PMC7212735; PMC10692865
The Psychological Burden: What GSM Does to a Woman's Inner Life The GENISSE study — a multicenter, observational study of 423 postmenopausal women with vaginal symptoms — used the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire to measure GSM's effects across four domains: daily activities, emotional wellbeing, sexual functioning, and self-perception/body image. The results were striking: the highest impact scores were in sexual functioning and self-perception/body image — ahead of daily activities and emotional wellbeing. Women with a GSM diagnosis showed significantly higher impact scores across all domains than those without. What GSM does to a woman's sense of herself and her sexual self is more disruptive, according to this research, than what it does to her daily logistics.
A qualitative study on the urinary dimension of GSM found that women with urgency and leaking reorganize their entire lives around anticipating and managing these symptoms — mapping bathrooms before any outing, declining social invitations, restricting travel, avoiding exercise, and withdrawing from situations they cannot fully control. The study's most resonant quote, used in the research itself as its title: 'As long as I have a restroom somewhere, I am fine.' This is not a minor quality-of-life issue. This is a woman whose freedom of movement has been contracted by a treatable medical condition she has not been able to name or discuss.
Research on urinary symptoms specifically found that they had a stronger impact on all DIVA domains — including emotional wellbeing, sexual functioning, and self-concept — than genital symptoms alone. The urgency, the leaking, the unpredictability are not just physically distressing — they produce anxiety, vigilance, shame, and a pervasive sense of bodily unreliability. A body that cannot be trusted to perform a basic biological function without warning or public consequence is a body that becomes a source of vigilance rather than ease.
Shame, Silence, and the Barrier to Care
The shame that surrounds GSM symptoms is not incidental — it is clinically significant and well-documented. Research consistently identifies embarrassment and shame as the primary reasons women do not seek treatment for GSM: they believe the symptoms are normal, unavoidable, and not something a clinician would want to hear about. They have absorbed the cultural message that a diminished pelvic and sexual experience after menopause is simply what happens to women's bodies; inevitable, unseemly to discuss, and their own problem to manage in silence.
This shame operates at multiple levels. There is shame about the specific symptoms themselves — the leaking, the pain with sex, the burning. There is shame about the sexual dimension of the symptoms, in a culture that has limited permission for older women to have or discuss sexual experience at all. And there is shame about the body itself: the sense that the body has become unreliable, embarrassing, a source of hidden management rather than a vehicle for living.
The clinical consequence is a presentation pattern in which GSM is almost never the presenting problem, even when it is the most clinically pressing one. Women discuss the depression, the anxiety, the relationship strain, the loss of intimacy and do not mention the vaginal dryness or the urgency that is driving all three. The GSM symptoms are pre-censored before the clinical conversation begins, because they carry so much shame that they do not feel mentionable. Clinicians who do not ask directly will often not be told.
This silence has a direct cost. A woman whose dyspareunia is producing sexual avoidance does not mention the dyspareunia — she presents the relationship tension. A woman whose urgency is driving social withdrawal does not mention the urgency — she presents the anxiety and depression. The presenting problem is treated while its physical driver goes unaddressed. Symptoms persist. The shame deepens.
"GSM remains extremely underdiagnosed despite its high prevalence, mostly because of reluctance among women to seek help due to embarrassment, or because of a tendency to consider these symptoms a normal feature of natural aging. Clinicians who do not ask directly will often not be told because the shame is pre-censored before the clinical conversation begins." — PMC7212735
The Sexual Avoidance Cycle — and Its Relational Consequences For sexually active women, GSM produces a specific and well-documented cycle that, without intervention, tends to be self-reinforcing. Dyspareunia — pain with intercourse — leads to anticipatory anxiety about sex: the expectation of pain produces fear, which produces physiological tension, which produces pelvic floor hypertonus and vaginismus (involuntary tightening of vaginal muscles), which makes the pain worse. The body learns to associate sexual activity with threat. Desire drops not because of hormonal changes to libido alone, but because the nervous system has learned — accurately — that sex is painful.
The ICSM 2024 recommendations on GSM make explicit a clinical point that is important for psychologists to understand: there is a bidirectional relationship between dyspareunia and hypoactive sexual desire disorder (HSDD). Pain with sex drives desire down. And reduced desire — in a relationship where a partner may not understand what is driving the change — produces its own relational consequences: the partner feels rejected, the woman feels guilty about the rejection, the couple's intimacy narrows, and the topic becomes too fraught to discuss. The GSM symptoms, which were always a treatable physical problem, have by this point generated a relational and psychological superstructure that requires its own therapeutic attention.
Research documents that the impact of GSM on quality of life is significantly higher in sexually active women — not because sexual activity worsens GSM, but because the collision between the desire for intimate connection and the physical experience of pain or discomfort produces a particular kind of distress: the grief of losing something that mattered, the shame of a body that seems to be refusing what the self still wants, and the relational distance that accumulates when the difficulty cannot be named.
What Effective Treatment Looks Like — and Why Fear Is Not a Reason to Avoid It
GSM is highly treatable. This is one of the most important and most under-communicated facts in postmenopausal women's health. And the treatment that is most effective, most specifically targeted, andmost supported by the clinical guidelines is local vaginal estrogen — not systemic hormone therapy, but low-dose estrogen applied directly to the vaginal tissue.
Local vaginal estrogen works by restoring estrogen to the urogenital tissues that depend on it: the vaginal mucosa, the urethral lining, and the bladder trigone. It does this with minimal systemic absorption — blood estrogen levels with low-dose vaginal estrogen remain within the normal postmenopausal range. The 2025 American Urological Association guidelines, the Menopause Society GSM Position Statement, and the NICE network meta-analyses all support local vaginal estrogen as the first-line treatment for GSM symptoms including recurrent UTIs, urinary urgency, and vaginal dryness. It is considered safe for long-term use in most women.
The most significant barrier to vaginal estrogen use is not medical — it is psychological and informational. Research documents that many women avoid local vaginal estrogen out of fear of breast cancer, a fear that is in many cases specifically generated by previously incorrect labeling on vaginal estrogen products that states breast cancer as a contraindication. Local vaginal estrogen, at low doses, does not carry the systemic risks associated with oral hormone therapy in older women. Women — and their clinicians — deserve accurate information about this distinction.
Non-hormonal options also exist for women who cannot or choose not to use vaginal estrogen: vaginal moisturizers used regularly (not only at the time of intercourse), lubricants for sexual activity, ospemifene (an oral SERM approved for dyspareunia), and intravaginal DHEA (prasterone). The therapeutic landscape for GSM has expanded considerably in recent years, and the clinical conversation should reflect that range.
The Role of Psychological Support in GSM
Because the psychological burden of GSM — the shame, the avoidance, the body image disruption, the relational consequences, the sexual anxiety cycle — develops alongside and often independently of the physical symptoms, medical treatment of GSM alone does not address all of what GSM has produced. A woman whose vaginal estrogen has successfully restored tissue health may still carry the anticipatory anxiety about sex that developed while intercourse was painful. She may still have the relational distance that accumulated during months or years of avoidance. She may still carry the shame about her body that was reinforced every time she did not mention her symptoms to a clinician.
Psychological support for GSM involves several specific areas of work. Shame reduction: naming explicitly that GSM is a common, treatable, medical condition — not a personal failure, not an inevitable consequence of aging, not something to manage in silence — and working with the specific shame narratives that have developed around it. Sexual anxiety: addressing the anticipatory pain-fear-tension cycle, which often requires both psychoeducation about the mechanism and graduated exposure work to rebuild positive associations with intimacy. Relationship repair: for women whose partnerships have been affected by sexual avoidance, couples therapy or individual work focused on communication and reconnection is often needed alongside medical treatment. And body image: the experience of GSM as a body that has become unreliable, embarrassing, or diminished is identity-level work, not just symptom-level work.
What I find consistently in clinical practice is that women who receive effective medical treatment for GSM without any psychological support often improve physically while continuing to avoid sex, continuing to carry shame, and continuing to manage their symptoms in silence from their partners. And women who receive psychological support without medical treatment for GSM often make meaningful progress in therapy while the physical symptoms that are driving the distress continue unaddressed. The most effective approach is integrated: medical treatment for the tissue changes, psychological support for everything those tissue changes produced.
If you are reading this article and recognizing yourself — if you have been mapping bathrooms, declining invitations, avoiding intimacy, or managing symptoms you have not been able to name — the most important thing this article can tell you is: this is GSM, it is treatable, and you do not have to manage it in silence.
About the Author
Dr. Julie Rashkis is a licensed psychologist and Menopause Society Certified Practitioner with over 20 years of clinical experience. Her Menopause Society certification encompasses clinical knowledge of GSM, its treatment, and its psychological dimensions — an integration that is rare among mental health providers. She specializes in the intersection of physical and psychological postmenopausal health. She is the founder of Therapy for Midlife, a virtual practice licensed in California and Wisconsin, seeing clients across all PSYPACT-participating states.
www.therapyformidlife.com | Book a free consultation
References
1. Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy. Menopause, 21(10), 1063-1068.
2. Simon, J. A., et al. (2025). GSM: Recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews.
3. Wasnik, V. B., Acharya, N., & Mohammad, S. (2023). GSM: A narrative review focusing on sexual health and quality of life. PMC10692865.
4. Palacios, S., et al. (2018). Impact of vaginal symptoms and GSM on well-being, functioning, and QoL in postmenopausal women: GENISSE study. PubMed 29944636.
5. Haeusler, S., et al. (2021). 'As long as I have a restroom somewhere, I am fine': Perspectives of peri- and postmenopausal women on the urinary component of GSM. PMC8573922.
6. Nappi, R. E., & Kokot-Kierepa, M. (2019). Addressing VVA/GSM for healthy aging in women. Frontiers in Endocrinology, 10, 561. 7. American Urological Association. (2025). AUA/SUFU/AUGS guideline on recurrent UTIs and GSM. AUA. 8. The Menopause Society. (2020). GSM position statement. menopause.org.
9. NICE. (2024). Network meta-analyses on GSM treatment. NICE guidelines.
10. PMC12445056. (2025). Women's experiences of their sexuality during the menopausal transition: Systematic review and meta-synthesis.
11. Thomas, H. N. (2018). High and dry: Recognizing the impact of genitourinary syndrome of menopause. Menopause, 25(12), 1401-1402.
